A Budget Impact Analysis of Single-Inhaler Extrafine Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Adult Patients with Uncontrolled Asthma in Mexico
Author(s)
José Ángel Paladio Hernández, MA, MS1, Angelica Hurtado-Vilchis, BA, MA2;
1PalaGod Health Supply, CEO, Mexico City, Mexico, 2Chiesi Mexico, Head of Commercial Operation, Mexico City, Mexico
1PalaGod Health Supply, CEO, Mexico City, Mexico, 2Chiesi Mexico, Head of Commercial Operation, Mexico City, Mexico
Presentation Documents
OBJECTIVES: Asthma is a major public health and economic challenge in Mexico due to its high prevalence and associated financial burden on healthcare systems. Current therapeutic options for adults with uncontrolled asthma, including inhaled- corticosteroids (ICS), long-acting β2-agonists (LABA), and long-acting muscarinic antagonists (LAMA), show significant cost variability, with some therapies imposing considerable economic strain on public institutions like the Mexican Social Security Institute (IMSS). Extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G, Trimbow®) has demonstrated superior efficacy by reducing exacerbations and lowering annual per-patient costs versus therapies prescribed at the IMSS. This study evaluates the budgetary impact of increasing BDP/FF/G prescription within IMSS through a Budget Impact Analysis (BIA).
METHODS: A BIA was conducted over a 5-year horizon to assess the economic implications of increasing BDP/FF/G use for uncontrolled asthma in adults at the IMSS. The analysis incorporated disease prevalence, medication market share distribution, drug acquisition costs, and exacerbation management expenses. Medication costs were derived from IMSS consolidated procurement data for 2024, and exacerbation costs were estimated using the Diagnosis-Related Groups (DRGs) framework published by IMSS. A baseline scenario with 20% BDP/FF/G market share in year one, increasing by 10% annually to 60% in year five, was compared against current treatment patterns. Results estimated the incremental BI for 1,000 adult patients.
RESULTS: The Budget Impact Analysis demonstrates that increasing the prescription of extrafine BDP/FF/G (Trimbow®) for uncontrolled asthma in adults represents a cost-saving intervention for the IMSS. Over a five-year horizon, increasing BDP/FF/G market share to 60% demonstrates an average projected savings of $74,523 per 1,000-patient cohort, translating to significant reductions in both medication expenses and costs associated with asthma exacerbations. The minimal budgetary impact difference (-0.014%) over this period underscores the economic sustainability of increasing BDP/FF/G prescription.
CONCLUSIONS: Results indicate that increasing BDP/FF/G prescription at the IMSS will lead to significant clinical and economic benefits.
METHODS: A BIA was conducted over a 5-year horizon to assess the economic implications of increasing BDP/FF/G use for uncontrolled asthma in adults at the IMSS. The analysis incorporated disease prevalence, medication market share distribution, drug acquisition costs, and exacerbation management expenses. Medication costs were derived from IMSS consolidated procurement data for 2024, and exacerbation costs were estimated using the Diagnosis-Related Groups (DRGs) framework published by IMSS. A baseline scenario with 20% BDP/FF/G market share in year one, increasing by 10% annually to 60% in year five, was compared against current treatment patterns. Results estimated the incremental BI for 1,000 adult patients.
RESULTS: The Budget Impact Analysis demonstrates that increasing the prescription of extrafine BDP/FF/G (Trimbow®) for uncontrolled asthma in adults represents a cost-saving intervention for the IMSS. Over a five-year horizon, increasing BDP/FF/G market share to 60% demonstrates an average projected savings of $74,523 per 1,000-patient cohort, translating to significant reductions in both medication expenses and costs associated with asthma exacerbations. The minimal budgetary impact difference (-0.014%) over this period underscores the economic sustainability of increasing BDP/FF/G prescription.
CONCLUSIONS: Results indicate that increasing BDP/FF/G prescription at the IMSS will lead to significant clinical and economic benefits.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE50
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies, Thresholds & Opportunity Cost
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)